Medical Policy Update Summary June 2019


Telehealth Commercial/Medicaid


Transcatheter Aortic Valve Replacement

  • Added positive coverage for valve-in-valve repair to a previously implanted valve

Radiofrequency Ablation of Tumors

  • Added unresectable intra-hepatic cholangiocarcinoma as covered indication

Insulin Delivery Devices and Continuous Glucose Monitoring Systems

  • Added Type 2 diabetes to long-term combined CGM/insulin-delivery devices section to coincide with FDA approvals
  • Added implantable glucose sensors (e.g., Eversense®) as investigational
  • Added pump/CGM replacement criteria